聖邦股份(300661.SZ):可行權的股票期權為123.9451萬份
格隆匯9月9日丨聖邦股份(300661.SZ)公佈,公司2018年股票期權激勵計劃首次授予股票期權代碼:036338;期權簡稱:聖邦JLC3。
公司 2018 年股票期權激勵計劃首次授予部分股票期權第二個行權期符合行權條件的激勵對象人數為273人,可行權的股票期權數量為123.9451萬份,行權價格為26.03元/股。
此次行權採用自主行權模式。 股票期權共分為四個行權期,第二個行權期行權期限為2021年9月13日起至2022年7月29日止。
第二個行權期可行權的股票期權若全部行權,公司股份仍具備上市條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.